Validation of Plasma Neurofilament Light Chain as a Marker for α-Synucleinopathies

Mov Disord. 2021 Nov;36(11):2701-2703. doi: 10.1002/mds.28724. Epub 2021 Aug 11.

Authors

Matthias Schmitz^#¹, Sezgi Canaslan^#¹, Anna Villar-Piqué^{1

2

3}, Karin Gmitterová^{1

4}, Daniela Varges¹, Paul Lingor^{5

6}, Franc Llorens^{1

2

3}, Peter Hermann¹, Fabian Maass⁷, Inga Zerr¹

Affiliations

¹ Department of Neurology, University Medical Center Göttingen and the German Center for Neurodegenerative Diseases, Göttingen, Germany.
² Network Center for Biomedical Research of Neurodegenerative Diseases, Institute Carlos III, Madrid, Spain.
³ Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Spain.
⁴ Second Department of Neurology, Comenius University and Department of Neurology, Slovak Medical University in Bratislava, Bratislava, Slovakia.
⁵ Department of Neurology, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.
⁶ German Center for Neurodegenerative Diseases, Munich, Germany.
⁷ Department of Neurology, University Medical Center, Göttingen, Germany.

^# Contributed equally.

PMID: 34379333
DOI: 10.1002/mds.28724

No abstract available

Keywords: biomarker; neurofilament light chain; α-synucleinopathies.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Humans
Intermediate Filaments
Synucleinopathies*

Substances

Biomarkers